Adlai Nortye Ltd American Depositary Shares (ANL) Stock Price, Quote & News

Company Profile

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is i...

Industry: Biotechnology

Sector: Healthcare

Phone: 848 230 7430

Website: www.adlainortye.com

Address:

New Jersey Biotechnology Dev Ctr, 2nd floor 685 US Hwy 1, North Brunswick, United States

ScanStock Jul. 21 at 6:56 PM

Insane run starting on ticker MLEC now! Are the low float mafia squeezing MLEC for 300% next?! Bulls shifting to MLEC. Wont be shocked to see a parabolic run 🚀🚀 $ANL $NUAI $ELPW wow

0 · Reply

Doom_Gloom_AR Jul. 21 at 4:16 AM

$ANL time for some butt stuff? Was trying for cheapies under 10, but never pulled the trigger.

1 · Reply

topstockalerts Jul. 15 at 6:54 PM

$ANL I’m starting to think this story has another chapter.

0 · Reply

Alt_Fuel Jul. 15 at 6:27 PM

$VSTM $ANL $ERAS $IMRX $RVMD August 28, 2023 Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-enters-discovery-and-development-collaboration

0 · Reply

focafoca99 Jul. 13 at 11:32 AM

$ANL added two top oncologists to its Scientific Advisory Board.

0 · Reply

Alt_Fuel Jul. 13 at 11:11 AM

$VSTM $ANL - July 13, 2026 Adlai Nortye Ltd. (NASDAQ: ANL) ... today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito. " ... pipeline is anchored by its RAS inhibitor programs, including AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody drug conjugate (ADC) leveraging our RASiCA(TM) (RAS Inhibitor Conjugated Antibody) platform, alongside our tri-specific immuno-oncology candidate AN8025. As we advance this portfolio, the scientific guidance from our newly formed SAB will be critical in shaping our R&D strategy and clinical development priorities, " said Carsten Lu, CEO & Chairman ... https://ir.adlainortye.com/news-releases/news-release-details/adlai-nortye-expands-scientific-advisory-board-appointment-two

0 · Reply

Alt_Fuel Jul. 10 at 5:21 PM

$VSTM $ANL $ERAS $IMRX $RVMD GenFleet Therapeutics - Hong Kong Daily chart - since IPO on September 19, 2025 ...

0 · Reply

Luckyizme Jul. 6 at 12:54 AM

$ANL Glad I sold this last month. Would like a nice dip for rentry

1 · Reply

JFais Jul. 2 at 8:15 PM

$ANL - seems on sale down here at $9.50

0 · Reply

Alt_Fuel Jun. 22 at 9:54 AM

$VSTM $ANL $ELTX $ERAS $RVMD RAS Inhibitors in Clinical Development

0 · Reply

Adlai Nortye doses first patient in AN9025 trial

Jul 16, 2026, 7:00 AM EDT - 8 days ago

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Jul 13, 2026, 7:00 AM EDT - 11 days ago

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

2026-06-22T11:37:12.000Z - 4 weeks ago

Cantor starts Adlai Nortye at Overweight, sees 180% upside

2026-06-22T10:15:22.000Z - 4 weeks ago

Adlai Nortye initiated with an Overweight at Cantor Fitzgerald

Jun 3, 2026, 5:30 PM EDT - 7 weeks ago

Adlai Nortye Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T11:20:07.000Z - 2 months ago

Adlai Nortye initiated with an Outperform at Oppenheimer

2026-05-14T16:11:06.000Z - 2 months ago

Adlai Nortye initiated with a Buy at JonesResearch

ERAS RVMD

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Adlai Nortye Registration statement: Registration filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Adlai Nortye Registration statement: Registration filing

2026-04-20T10:21:49.000Z - 3 months ago

Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright

Apr 16, 2026, 7:00 AM EDT - 3 months ago

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

2026-04-15T14:15:36.000Z - 3 months ago

Adlai Nortye Ltd (ADR) trading resumes

2026-04-15T13:36:44.000Z - 3 months ago

Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

Apr 10, 2026, 7:00 AM EDT - 3 months ago

Adlai Nortye Annual report: Q4 2025

2026-03-20T10:37:59.000Z - 4 months ago

Leerink bullish on Adlai Nortye, initiates with an Outperform

2026-03-20T10:16:32.000Z - 4 months ago

Adlai Nortye initiated with an Outperform at Leerink

2026-03-10T12:59:01.000Z - 4 months ago

Adlai Nortye files to sell $600M of Class A ordinary shares

2026-03-10T12:58:30.000Z - 4 months ago

Adlai Nortye files to sell 64.62M Class A ordinary shares for holders

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Adlai Nortye Registration statement: Registration Filing

2026-02-13T14:45:43.000Z - 5 months ago

Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic

2026-02-13T14:41:06.000Z - 5 months ago

Adlai Nortye upgraded to Buy from Neutral at H.C. Wainwright

Feb 12, 2026, 4:00 AM EST - 5 months ago

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

2026-02-03T12:10:38.000Z - 6 months ago

Adlai Nortye prices 64.6M shares at $2.17 in private placement

Feb 3, 2026, 7:00 AM EST - 6 months ago

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

2026-01-30T14:45:22.000Z - 6 months ago

Adlai Nortye Ltd (ADR) trading resumes

2026-01-30T14:40:32.000Z - 6 months ago

Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

2026-01-29T11:11:30.000Z - 6 months ago

Adlai Nortye initiated with a Buy at Lucid Capital

2025-12-29T11:10:52.000Z - 7 months ago

Adlai Nortye enters exclusive license agreement with ASK Pharm for AN9025

Dec 29, 2025, 6:00 AM EST - 7 months ago

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Oct 13, 2025, 11:07 PM EDT - 10 months ago

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-06-02T15:25:22.000Z - 1 year ago

Adlai Nortye downgraded to Neutral from Buy at H.C. Wainwright

May 30, 2025, 7:00 AM EDT - 1 year ago

Adlai Nortye Slides: Corporate Presentation

Apr 30, 2025, 3:30 AM EDT - 1 year ago

Adlai Nortye Annual report: Q4 2024

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Adlai Nortye Slides: Investor Presentation

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Adlai Nortye Slides: Investor Presentation

Nov 11, 2024, 7:00 AM EST - 1 year ago

Adlai Nortye Slides: Investor Presentation

Sep 14, 2024, 7:00 AM EDT - 2 years ago

Adlai Nortye Slides: Investor Presentation

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Adlai Nortye Earnings release: Q2 2024

Jul 8, 2024, 7:00 AM EDT - 2 years ago

Adlai Nortye Slides: Corporate Presentation

Jun 19, 2024, 7:00 AM EDT - 2 years ago

Adlai Nortye Slides: Corporate Presentation

May 23, 2024, 9:03 PM EDT - 2 years ago

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

May 22, 2024, 8:00 AM EDT - 2 years ago

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Adlai Nortye Annual report: Q4 2023

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Adlai Nortye Slides: Corporate Presentation

Mar 29, 2024, 6:00 AM EDT - 2 years ago

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Dec 25, 2023, 7:00 AM EST - 2 years ago

Adlai Nortye Slides: Corporate Presentation

Nov 17, 2023, 7:30 AM EST - 2 years ago

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Oct 23, 2023, 8:12 AM EDT - 2 years ago

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Oct 3, 2023, 12:05 PM EDT - 3 years ago

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Sep 29, 2023, 2:46 AM EDT - 3 years ago

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Sep 27, 2023, 8:00 AM EDT - 3 years ago

Adlai Nortye Registration statement: Registration Filing

Sep 12, 2023, 8:00 AM EDT - 3 years ago

Adlai Nortye Registration statement: Registration Filing

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Adlai Nortye Registration statement: Registration Filing

Aug 11, 2023, 7:05 AM EDT - 3 years ago

Cancer treatment company Adlai Nortye sets terms in IPO

ScanStock Jul. 21 at 6:56 PM

Insane run starting on ticker MLEC now! Are the low float mafia squeezing MLEC for 300% next?! Bulls shifting to MLEC. Wont be shocked to see a parabolic run 🚀🚀 $ANL $NUAI $ELPW wow

0 · Reply

Doom_Gloom_AR Jul. 21 at 4:16 AM

$ANL time for some butt stuff? Was trying for cheapies under 10, but never pulled the trigger.

1 · Reply

topstockalerts Jul. 15 at 6:54 PM

$ANL I’m starting to think this story has another chapter.

0 · Reply

Alt_Fuel Jul. 15 at 6:27 PM

0 · Reply

focafoca99 Jul. 13 at 11:32 AM

$ANL added two top oncologists to its Scientific Advisory Board.

0 · Reply

Alt_Fuel Jul. 13 at 11:11 AM

0 · Reply

Alt_Fuel Jul. 10 at 5:21 PM

$VSTM $ANL $ERAS $IMRX $RVMD GenFleet Therapeutics - Hong Kong Daily chart - since IPO on September 19, 2025 ...

0 · Reply

Luckyizme Jul. 6 at 12:54 AM

$ANL Glad I sold this last month. Would like a nice dip for rentry

1 · Reply

JFais Jul. 2 at 8:15 PM

$ANL - seems on sale down here at $9.50

0 · Reply

Alt_Fuel Jun. 22 at 9:54 AM

$VSTM $ANL $ELTX $ERAS $RVMD RAS Inhibitors in Clinical Development

0 · Reply

Alt_Fuel Jun. 15 at 8:48 PM

$VSTM $ANL $ELTX $ERAS $RVMD June 15, 2026-- Verastem Oncology today announced it will host an investor conference call & webcast on Tuesday, June 23 at 4:30 pm ET to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D clinical program and updated preliminary data from the Phase 1/2 TARGET-D 101 dose escalation and dose expansion trial evaluating VS-7375 alone and in combination in patients with KRAS G12D-mutated advanced solid tumors. During the call, Verastem’s management team will present preliminary data from the TARGET-D 101 dose-escalation and dose expansion cohorts across pancreatic, colorectal, and non-small lung cancers, including updated safety and tolerability, pharmacokinetic findings, as well as patient case studies evaluating VS-7375 both as a monotherapy and in combination across multiple tumor types. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-host-investor-conference-call-and-report

0 · Reply

FatherofTrades Jun. 5 at 12:09 AM

PRIDE MONTH MEME STOCKS I WANT TO SEE PUMP FOR THE LOLS: $GAYMF $ANL $BSY

2 · Reply

SuperGreenToday Jun. 3 at 12:29 PM

$ANL

0 · Reply

FDAvalid Apr. 27 at 10:55 PM

$ANL $ELTX $ERAS $RVMD $VSTM Bulls: “ERAS is breathing easy!” 😌📈 8K: Death from Grade 3 pneumonitis ➡️ Grade 5 🪦 Market: starts hyperventilating 😮‍💨📉 You can’t steroid your way out of this chart 📊�

1 · Reply

DailyWatcher_ Apr. 25 at 9:56 PM

People who comment on $RVMD RM-055 preclinical data as predicting replacement to Pan RAS molecule glues should try to understand how the drug works from detailed slides at RVMD website. Daraxonrasib causes some level of GTP hydrolysis and contributes to enhancing RAS off$ERAS and $ANL ) also kill cell lines with RAS amplification. Phase 1 to start in q 4. And people need to stop being ahead of themselves. Although Cool discovery but no details on how it enhances hydrolysis.

0 · Reply

Alt_Fuel Apr. 24 at 8:29 AM

$VSTM Verastem partner in KRAS ON / OFF " GenFleet Therapeutics " - New 52 Week High on April 24, 2026 $ANL $ELTX $ERAS $RVMD Apr. 23, 2026-- Verastem Oncology $VSTM will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-report-first-quarter-2026-financial-results

1 · Reply

StockScanners Apr. 21 at 3:31 AM

$ANL reached 17.30

0 · Reply

Alt_Fuel Apr. 20 at 5:42 PM

$VSTM $ANL $ELTX $ERAS $RVMD BTIG Reiterates Buy on Verastem, Maintains $19 Price Target 01:12 PM EDT, April 20, 2026 Updated 27 minutes ago, April 20, 2026 at 1:12 PM EDT 1:12 PM EDT, April 20, 2026 (Benzinga Newswire) BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.

1 · Reply

DARKP00L Apr. 20 at 10:14 AM

$ANL 06:14 on Apr. 20 2026 HC Wainwright & Co. Maintains Buy on Adlai Nortye, Raises Price Target to $20 #tradeideas

0 · Reply

outlawinvestor1 Apr. 19 at 3:56 PM

ras targeted small molecule landscape (not comprehensive). $RVMD $ERAS $VSTM $ANL

1 · Reply

StockScanners Apr. 18 at 3:19 AM

$ANL keep watch if this holds above 15.37

0 · Reply

Market Cap	57.20M
Revenue (ttm)	0.00
Net Income (ttm)	-51.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.03

Volume	846
Avg Vol	19,594
Day's Range	N/A - N/A
Shares Out	36.90M
Stochastic %K	21%
Beta	-0.83
Analysts	Hold
Price Target	$9.00